Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2016 (2016), Article ID 6385276, 3 pages
Case Report

Botulinum Toxin A Injection in the Bladder Neck: A Promising Treatment for Urinary Retention

1University of Balamand, St. George Hospital University Medical Center (SGHUMC), Beirut 1100 2807, Lebanon
2Collaborateur Scientifique d’Urologie, CHU St. Pierre, 1000 Brussels, Belgium

Received 10 January 2016; Accepted 25 February 2016

Academic Editor: ChunHou Liao

Copyright © 2016 Marianne Alam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Cantlay and H. N. Raghallaigh, “Benign prostatic hyperplasia,” InnovAiT: Education and Inspiration for General Practice, vol. 8, no. 4, pp. 238–245, 2015. View at Publisher · View at Google Scholar
  2. C. Roehrborn, “Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates: Chuang Y-C, Chiang P-H, Huang C-C et al (Chang Gung Mem Hosp, Kaohsiung, Taiwan; Univ of Pittsburgh, Pa) Urology 66:775–779, 2005,” Yearbook of Urology, vol. 2006, pp. 125–127, 2006. View at Google Scholar · View at Scopus
  3. T. Leippold, A. Reitz, and B. Schurch, “Botulinum toxin as a new therapy option for voiding disorders: current state of the art,” European Urology, vol. 44, no. 2, pp. 165–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Bhidayasiri and D. D. Truong, “Expanding use of botulinum toxin,” Journal of the Neurological Sciences, vol. 235, no. 1-2, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Blok, J. Pannek, D. Castro Diaz et al., Guidelines on Neuro-Urology, Uroweb, 2015,
  6. A. Oeconomou, H. Madersbacher, G. Kiss, T. J. Berger, M. Melekos, and P. Rehder, “Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature,” European Urology, vol. 54, no. 4, pp. 765–777, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. C. Chuang, “Minimally invasive therapy for BPH,” Incontinence and Pelvic Floor Dysfunction, vol. 1, supplement 2, pp. 21–24, 2007. View at Google Scholar
  8. M. Jasinski, T. Drewa, J. Tyloch, and Z. Wolski, “N56 Is botulinum toxin type A intraprostatic injections effective in patients with urinary retention?” European Urology Supplements, vol. 8, no. 8, pp. 587–588, 2009. View at Publisher · View at Google Scholar
  9. Y.-C. Chuang, P.-H. Chiang, N. Yoshimura, F. De Miguel, and M. B. Chancellor, “Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia,” BJU International, vol. 98, no. 5, pp. 1033–1037, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. T. A. McNicholas, H. H. Woo, P. T. Chin et al., “Minimally invasive prostatic urethral lift: surgical technique and multinational experience,” European Urology, vol. 64, no. 2, pp. 292–299, 2013. View at Publisher · View at Google Scholar · View at Scopus